256 research outputs found
Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active Psoriatic Arthritis
Objective To assess long-term efficacy and safety of guselkumab, an interleukin-23 p19 subunit (IL-23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III DISCOVER-2 trial. Methods In the DISCOVER-2 trial, patients with active PsA (>= 5 swollen joints and >= 5 tender joints; C-reactive protein level >= 0.6 mg/dl) despite prior nonbiologic therapy were randomized to receive the following: guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks; or placebo with crossover to guselkumab 100 mg every 4 weeks, beginning at week 24. Efficacy assessments included American College of Rheumatology >= 20%/50%/70% improvement criteria (ACR20/50/70), Investigator's Global Assessment (IGA) of psoriasis score of 0 (indicating complete skin clearance), resolution of enthesitis (Leeds Enthesitis Index) and dactylitis (Dactylitis Severity Score), and changes in the Sharp/van der Heijde modified radiographic scores for PsA. Clinical data (imputed as no response/no change from baseline if missing) and observed radiographic data were summarized through week 100; safety assessments continued through week 112. Results Of the 739 randomized and treated patients, 652 (88%) completed treatment through week 100. Across groups of guselkumab-treated patients (including those in the placebo-guselkumab crossover group), the following findings at week 100 indicated that amelioration of arthritis signs/symptoms and extraarticular manifestations was durable through 2 years: ACR20 response (68-76%), ACR50 response (48-56%), ACR70 response (30-36%), IGA score of 0 (55-67%), enthesitis resolution (62-70%), and dactylitis resolution (72-83%). Mean changes in the Sharp/van der Heijde modified score for PsA from weeks 52 to week 100 (range 0.13-0.75) indicated that the low rates of radiographic progression observed among guselkumab-treated patients at earlier time points extended through week 100. Through week 112, 8% (5.8 per 100 patient-years) and 3% (1.9 per 100 patient-years) of the 731 guselkumab-treated patients had a serious adverse event or serious infection, respectively; 1 death occurred (road traffic accident). Conclusion In biologic-naive PsA patients, guselkumab provided durable improvements in multiple disease domains with no unexpected safety findings through 2 years.Pathophysiology and treatment of rheumatic disease
Optimal convergecast scheduling for hierarchical wireless industrial systems: performance bounds and twoâstage algorithms
Direct Measurements of the Branching Fractions for and and Determinations of the Form Factors and
The absolute branching fractions for the decays and
are determined using singly
tagged sample from the data collected around 3.773 GeV with the
BES-II detector at the BEPC. In the system recoiling against the singly tagged
meson, events for and events for decays are observed. Those yield
the absolute branching fractions to be and . The
vector form factors are determined to be
and . The ratio of the two form
factors is measured to be .Comment: 6 pages, 5 figure
Measurements of J/psi Decays into 2(pi+pi-)eta and 3(pi+pi-)eta
Based on a sample of 5.8X 10^7 J/psi events taken with the BESII detector,
the branching fractions of J/psi--> 2(pi+pi-)eta and J/psi-->3(pi+pi-)eta are
measured for the first time to be (2.26+-0.08+-0.27)X10^{-3} and
(7.24+-0.96+-1.11)X10^{-4}, respectively.Comment: 11 pages, 6 figure
BESII Detector Simulation
A Monte Carlo program based on Geant3 has been developed for BESII detector
simulation. The organization of the program is outlined, and the digitization
procedure for simulating the response of various sub-detectors is described.
Comparisons with data show that the performance of the program is generally
satisfactory.Comment: 17 pages, 14 figures, uses elsart.cls, to be submitted to NIM
Measurement of branching fractions for the inclusive Cabibbo-favored ~K*0(892) and Cabibbo-suppressed K*0(892) decays of neutral and charged D mesons
The branching fractions for the inclusive Cabibbo-favored ~K*0 and
Cabibbo-suppressed K*0 decays of D mesons are measured based on a data sample
of 33 pb-1 collected at and around the center-of-mass energy of 3.773 GeV with
the BES-II detector at the BEPC collider. The branching fractions for the
decays D+(0) -> ~K*0(892)X and D0 -> K*0(892)X are determined to be BF(D0 ->
\~K*0X) = (8.7 +/- 4.0 +/- 1.2)%, BF(D+ -> ~K*0X) = (23.2 +/- 4.5 +/- 3.0)% and
BF(D0 -> K*0X) = (2.8 +/- 1.2 +/- 0.4)%. An upper limit on the branching
fraction at 90% C.L. for the decay D+ -> K*0(892)X is set to be BF(D+ -> K*0X)
< 6.6%
Study of
New data are presented on from a sample of 58M
events in the upgraded BES II detector at the BEPC. There is a
conspicuous signal for and a peak at higher mass which
may be fitted with . From a combined analysis with
data, the branching ratio
is at the 95%
confidence level.Comment: 11 pages, 5 figures. Submitted to Phys. Lett.
Search for the Lepton Flavor Violation Processes and
The lepton flavor violation processes and are
searched for using a sample of 5.8 events collected with
the BESII detector. Zero and one candidate events, consistent with the
estimated background, are observed in and
decays, respectively. Upper limits on the branching ratios are determined to be
and at the 90% confidence level (C.L.).Comment: 9 pages, 2 figure
The pole in
Using a sample of 58 million events recorded in the BESII detector,
the decay is studied. There are conspicuous
and signals. At low mass, a large
broad peak due to the is observed, and its pole position is determined
to be - MeV from the mean of six analyses.
The errors are dominated by the systematic errors.Comment: 15 pages, 6 figures, submitted to PL
Measurements of Cabibbo Suppressed Hadronic Decay Fractions of Charmed D0 and D+ Mesons
Using data collected with the BESII detector at storage ring
Beijing Electron Positron Collider, the measurements of relative branching
fractions for seven Cabibbo suppressed hadronic weak decays ,
, and , , and are presented.Comment: 11 pages, 5 figure
- âŠ